The growth factor erythropoietin (EPO) and erythropoietin receptors (EPOR) are expressed in the nervous system. Neuronal expression of EPO and EPOR peaks during brain development and is upregulated in the adult brain after injury. Peripherally administered EPO, and at least some of its variants, cross the blood-brain barrier, stimulate neurogenesis, neuronal differentiation, and activate brain neurotrophic, antiapoptotic, anti-oxidant and anti-inflammatory signaling. These mechanisms underlie their tissue protective effects in nervous system disorders. As the tissue protective functions of EPO can be separated from its stimulatory action on hematopoiesis, novel EPO derivatives and mimetics, such as asialo-EPO and carbamoylated EPO have been developed. While the therapeutic potential of the novel EPO derivatives continues to be characterized in preclinical studies, the experimental findings in support for the use of recombinant human (rh)EPO in human brain disease have already been translated to clinical studies in acute ischemic stroke, chronic schizophrenia, and chronic progressive multiple sclerosis. In this review article, we assess the studies on EPO and, in particular, on its structural or functional variants in experimental models of nervous system disorders, and we provide a short overview of the completed and ongoing clinical studies testing EPO as neuroprotective/neuroregenerative treatment option in neuropsychiatric disease.
INTRODUCTION
The growth factor erythropoietin (EPO) has been originally known for and named after its potent stimulation of erythropoiesis. 1 Apart from their hematopoietic actions, EPO and EPO variants are directly neuroprotective in cell culture models and after application in the brain. [2] [3] [4] [5] [6] Moreover, several EPO variants that do not bind to EPO receptors (EPOR) in myeloid cells, and that lack hematopoietic activity, display potent tissue protective activities. 7, 8 Expression of EPO and its receptors in the nervous system, as well as its multifaceted protective actions in cell culture and animal models (e.g., induction of anti-apoptotic, anti-oxidant and anti-inflammatory signaling in neurons, glial and cerebrovascular endothelial cells, stimulation of angiogenesis, and neurogenesis), have been reported extensively and reviewed in detail elsewhere. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] Therefore, this review will focus on 1) preclinical work published on EPO variants and 2) clinical studies in neuropsychiatric disease performed with EPO.
EPO SIGNALING IN THE NERVOUS SYSTEM
EPO and its receptor are expressed in the developing brain. 18 -20 The weak constitutive expression in the adult brain can be rapidly increased by hypoxia and acute metabolic stress as evidenced by detection of EPO in cerebrospinal fluid or postmortem brain tissue after traumatic brain injury, subarachnoid hemorrhage, and stroke. 12, 13, [21] [22] [23] [24] Hypoxia-induced expression of EPO and the classical EPOR in brain cells may contribute to ischemic tolerance, 16, 25 whereas neutralization of the brain endogenous EPO augments ischemic damage. 4 In fact, EPOR-deficient mice show increased apoptosis in the brain and enhanced hypoxia sensitivity. 26 Interestingly, EPOR is also up-regulated in chronic brain disease (e.g., schizophrenia and Alzheimer's disease [AD] ), potentially reflecting ongoing metabolic distress. 27, 28 EPO acts by binding to its specific transmembrane receptor (EPOR). The classical EPOR in hematopoietic cells is a cytokine type I receptor characterized by an extracellular N-terminal domain with conserved cysteines and a WSXWS-motif, a single hydrophobic transmembrane segment, and a cytosolic domain with no intrinsic kinase activity. 29 Homodimerization of the two transmembrane EPOR molecules binds one EPO molecule and leads to a conformational change, which in turn activates EPOR associated Janus family tyrosine kinase 2 (JAK2) molecules. Once activated, JAK2 phosphorylates distal parts of the receptors, which subsequently serve as docking sites for downstream signaling molecules. Multiple signal transduction pathways are activated downstream of EPOR/JAK2. 8, 29 In neurons these include signal transducers and activators of transcription (Stat), phosphatidylinositol 3-kinase (PI3K)/Akt, Ras/extracellular signal regulated kinase (ERK1/2), nuclear factor-kappa-B (NF-B), and calcium. 6, 7, 30, 31 Brines and Cerami 7 have proposed that the cytoprotective effects of EPO and its nonhematopoietic derivative, the carbamoylated EPO (CEPO) are mediated by a heteromeric receptor complex comprised of one EPOR subunit and a dimer of the common beta-chain shared by the members of the interleukin-3 receptor family. 32, 33 The molecular assembly of this proposed heteroreceptor has been projected from that of the known stoichiometry of the granulocyte-macrophage colony-stimulating factor receptor complex. 7, 32 The authors demonstrated that the common beta-chain can be co-immunoprecipitated with EPOR antibodies from the P19 embryonal carcinoma cell line. 32 Loss of some of the cytoprotective effects of EPO and CEPO in mice lacking the common betachain, 32, 33 together with the immunohistochemical observations on similarities in the expression pattern of the common beta-chain and the classical EPOR in rat spinal cord 32, 34 support their hypothesis, but a concrete proof for the existence of the proposed heteromeric receptor structure in primary brain cells or tissues is lacking. In a recent study, no expression of the common beta-chain could be detected in neuronal cell lines that respond to EPO. 35 Furthermore, studies in mice harboring a brain specific genetic ablation of the classical EPOR have shown that expression of the EPOR is indispensable for EPO-induced neurogenesis and neuroprotection. 36 -38 In contrast, CEPO stimulates adult neurogenesis in the EPOR-knock-out mice suggesting that the cellular signaling by CEPO does not involve the classical EPOR. 38 Future studies are still needed to clarify whether the classical EPOR, the proposed heteromer or another yet unidentified brain specific EPOR mediate the actions of EPO and its structural variants on brain cells.
EPO STRUCTURAL AND FUNCTIONAL VARIANTS: ANALOGUES, DERIVATIVES, MIMETICS AND ENDOGENOUS STIMULATORS OF EXPRESSION
Stimulation of erythropoiesis using recombinant human EPO (rhEPO) has been a medical and economic success story. To improve/modify the properties of EPO with respect to its pharmacokinetic and pharmacodynamic profile and, last but not least, to compensate for expired EPO patent protection and gain an erythropoiesis stimulating agent (ESA) market share, a number of EPO variants (see FIG. 1 Betahydroxybuturate HIF-stabilizer ϩ ϩ Likely aa ϭ amino acids; BBB ϭ blood-brain barrier; CERA ϭ continuous erythropoiesis receptor activator; EAE ϭ experimental autoimmune encephalomyelitis; EP ϭ erythropoiesis; EMP ϭ EPO mimetic peptide; EPO ϭ erythropoietin; GATA-2 ϭ GATA binding protein 2; HIF ϭ hypoxia-inducible factor; ip ϭ intraperitoneal; iv ϭ intravenous; kDa ϭ kiloDalton; n.d. ϭ not determined; NP ϭ neuroprotection; NP dose equivalent rhEPO ϭ dose equivalent to rhEPO for neuroprotection; rhEPO ϭ recombinant human erythropoietin; sc ϭ subcutaneous; T1/2 ϭ half life. Suggested to bind to EPOR-␤ common receptor heteromer; short T1/2, for pHBSP in rats and rabbits 2min iv; Neuroprotective in animal models of stroke, sciatic nerve compression, diabetic retinopathy, improved performance in novel object recognition test More challenging and certainly more important than producing "me-too ESA compounds" will be the development of predominantly neuroprotective/tissue protective EPO variants. Since the original discovery of the neuroprotective potential of EPO more than a decade ago, [2] [3] [4] 40 attempts to separate the hematopoietic actions of EPO from its tissue protective effects have resulted in identification of novel nonhematopoietic EPO derivatives. 7, 8, 33, [41] [42] [43] [44] [45] In addition to the development of structurally related EPO derivatives 1, 8, 39, 46 or mimetics 41, 42, [47] [48] [49] [50] (i.e., structural variants) that target EPOR, compounds that act by induction of EPO gene expression (i.e., functional EPO variants), such as HIF-stabilizers [51] [52] [53] [54] and GATA-2 inhibitors 1,39 are actively pursued as alternatives to EPO for stimulation of erythropoiesis, and ultimately also for neuroprotection (FIG. 1) . The advantages and disadvantages of agents that ubiquitously induce a wide spectrum of hypoxia-inducible genes are presently not known. In particular, the question whether these agents have benefits over the use of rhEPO in treatment of nervous system disorders remains to be addressed. The main properties of EPO variants are summarized in Table 1 .
ERYTHROPOIETIN VARIANTS AS NEUROPROTECTIVE/NEUROREGENERATIVE TREATMENT: PRECLINICAL STUDIES

Stroke and cerebral ischemia
The beneficial effects of EPO and its variants in models of experimental stroke and cerebral hypoxia-ischemia can be attributed to a multitude of cytoprotective mechanisms, including inhibition of apoptosis, anti-inflammatory and anti-oxidant actions, restoration of blood-brain barrier integrity, stimulation of neurogenesis and angiogenesis. 6, 33, 44, [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] Earlier studies used the direct intracerebroventricular route of administration of EPO to demonstrate its potent tissue protective activity in focal and global models of cerebral ischemia.
2-4 EPO, as a large, highly glycosylated negatively charged molecule, was not expected to penetrate the blood-brain barrier. 65, 66 The first evidence for a neuroprotective effect of EPO by peripheral route of administration was published by Brines et al. 67 with the demonstration that an intraperitoneal injection of high dose rhEPO (Epoetin alpha, 5000 U/kg) up to 6 h after reperfusion resulted in reduction of infarct volumes in a focal stroke model in rats. Immunohistochemical detection of biotinylated rhEPO 5 h after its intraperitoneal injection at the therapeutically effective dose (5000 U/kg) showed that rhEPO crosses the blood-brain barrier in the rat. 67 The transfer of circulating EPO across the blood-brain barrier in therapeutically effective concentrations has since been confirmed in several species, including man. 21,27,68 -72 It is important to note, however, that the amount of EPO reaching the brain is only in the range of 1% of the intravenously applied protein, thus explaining the high doses required for brain protection. Intriguingly, EPO and its derivatives reduce histological damage and improve functional outcome when given as intraperitoneal or even intranasal post-treatment after experimental stroke and hypoxia-ischemia. 33, 44, [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] 73 A typical example of the functional improvement by EPO in sensorimotor deficits after a focal stroke is presented in Figure 2 (Sirén and Ehrenreich, unpublished own preclinical data in preparation of the "Göttingen EPO Stroke Study," see as follows).
A comprehensive dosing study using post-treatment with EPO starting at 6 h after an embolic middle cerebral artery (MCA) occlusion in rats demonstrated dose-dependent reduction of functional deficits and infarct volume up to 28 days after MCA occlusion. 58 The hematocrit was transiently increased at all dose levels of EPO with a peak at 14 days after the initial dose.
58 CEPO (50 g/kg) induced protective effects equal to the highest dose of EPO (5000 U/kg equivalent to 46 g/kg) without increasing hematocrit. 58 As summarized in Table 1 , neuroprotection in experimental stroke can be achieved with CEPO and other nonhematopoietic derivatives of EPO (asialo-EPO, Caranesp, EPO-S100E) at equipotent doses to that of rhEPO. Whether the lack of effect on hematopoiesis in the acute clinical setting represents a clear advantage over the use of rhEPO remains to be verified in future studies. Like the native protein, the nonhematopoietic derivatives of EPO are large proteins with the potential to induce antibody formation.
74,75
Traumatic brain injury and spinal cord injury
EPO and EPO variants improve morphological, functional and cognitive recovery in experimental models of traumatic brain injury. 67,76 -86 Brain edema after experimental injury can effectively be attenuated by posttreatment with EPO. 76, 78, 83 Mechanisms which account for the beneficial actions after traumatic injuries include inhibition of apoptosis, anti-inflammatory and anti-oxidant actions, restoration of blood-brain barrier integrity, stimulation of neurogenesis, and angiogenesis, 7,8,67,76 -84 but it is not yet clear which of the neuroprotective effects of EPO are responsible for the long-term prevention of trauma-induced brain atrophy, cognitive and neurobehavioral dysfunction. 86 Recovery of both motor function and reduction of the histopathological damage by EPO and its nonerythropoietic derivatives CEPO and asialo-EPO have been reported in various, but not all, models of spinal cord injury. 33 ,34,43,87-90
FIG. 2.
Erythropoietin (EPO) reduces motor deficits and sensorimotor neglect in an experimental stroke model in rats. Unilateral hypoxia-ischemia (HI) was induced by ligation of the right carotid artery followed by exposure to hypoxia (8% oxygen) for 40 min in 28-day-old Wistar/Imamichi rats. Epoetin alpha (5000 U/kg) was given intraperitoneally immediately before and 24 and 48 h after exposure to hypoxia. After habituation to test environment and handling, the rats were tested daily for motor function (balance on a 1.6 cm diameter round beam for 60 s, panel [A]), and for sensorimotor asymmetry (the cylinder test, panel [B]) 4 days before (pre-HI) and 6 days after HI insult. In the cylinder test, each weight-bearing contact of the initial forepaw with the wall during full rear was counted for a 3-min period. Mean Ϯ standard error of the mean. Statistical analysis: two-sided t-test.
Neuroinflammation, retinal disease, and peripheral nerve damage
In experimental autoimmune encephalomyelitis (EAE), an animal model for multiple sclerosis (MS), EPO derivatives improve functional recovery, reduce tissue damage, inflammatory responses, and blood-brain barrier leakage. 33, 67, [91] [92] [93] [94] [95] [96] Neuronal damage associated with cerebral malaria and radiosurgically-induced brain injury in mice can also be reduced by EPO and CEPO. [97] [98] [99] Translational relevance of these data is emphasized by a recent clinical study demonstrating that high plasma levels of EPO are associated with reduced risk of neurological sequelae in children with cerebral malaria. 100 Beneficial effects of both EPO and its nonhematopoietic derivatives and mimetics have been described in models of peripheral axonal nerve injury, injury-induced Wallerian degeneration, diabetic, and HIV-associated neuropathy. 41, [101] [102] [103] [104] [105] In these conditions, the anti-cytokine, antiapoptotic, anti-oxidative, and trophic effects on both neurons and oligodendrocyte progenitor cells are likely to reduce inflammation and preserve myelination and neuronal function. 33, 67, [91] [92] [93] [94] [95] [96] [97] [98] 102, 103 The initial observation by Grimm et al. 106 of a potent neuroprotective effect of EPO in light-induced retinal degeneration has been confirmed in many other models of retinal disease in which EPO derivatives are in consideration for clinical use. 7,106 -109 Here, a local intravitreal administration has been proposed to avoid neovascularization and angiogenesis after systemic EPO therapy. 108, 110 Interestingly, timing of the therapy seems to have a decisive role for the outcome in models of hypoxia-induced retinopathy, whereas early administration of EPO protects retinal neurons against hypoxia-induced apoptosis and prevents hypoxia-induced neovascularization, late EPO treatment fails to protect the retina and enhances pathological neovascularization.
107
Neurodegeneration
Based on their pharmacological profile, EPO derivatives would be expected to counteract degenerative processes in experimental models of chronic neurodegeneration, such as AD. Although increased expression of EPOR in the brains of AD patients 28 together with the findings demonstrating protection by EPO against betaamyloid toxicity in cultured neurons 111 support a role for EPO derivatives in this prototype of neurodegenerative disorders, no data on effects of EPO derivatives in animal models of AD are available thus far. Slight improvements in functional outcome with variable efficacy to reduce histological damage have indeed been reported in models of Parkinson disease and amyotrophic lateral sclerosis (ALS) in which these compounds presumably act by inducing anti-oxidant enzymes, inhibiting apoptosis, and stimulating axonal regeneration. [112] [113] [114] [115] Furthermore, EPO improved graft survival of embryonic ventral mesencephalic dopamine neurons when transplanted into the striatum of 6-hydroxy-dopamine lesioned rats. 116 However, treatment with asialo-EPO failed to reduce cell death or modify disease progression in a mouse model of Huntington's disease. 117 Clearly, the rapidly growing evidence of neuroprotection by EPO (and EPO variants) in animal models of brain disease and peripheral nerve injury awaits its translation into clinical studies in nervous system disorders. In the case of acute ischemic stroke, the preclinical evidence meets most of the Stroke Therapy Academic Industry Roundtable (STAIR) criteria, 118 such as testing by several laboratories, using both temporary and permanent stroke models, peripheral application as post-treatment at several doses, and exploration of therapeutic window, characterization of its pharmacokinetic profile in respect to blood-brain barrier penetration after peripheral administration, measurement of histological, and functional outcome with prolonged survival. Conceptually, the nonhematopoietic variants of EPO would be expected to provide an advantage over EPO in the clinical setting for brain and nervous system indications. In diseases like MS, however, the very weak hematopoietic effects of EPO, leading additionally to disease-beneficial shifts in iron stores, may make these variants unnecessary (see below). 119 Also, the safety and efficacy of these novel compounds in man need first to be confirmed in phase I studies.
ERYTHROPOIETIN AS NEUROPROTECTIVE/ NEUROREGENERATIVE TREATMENT STRATEGY FOR HUMAN BRAIN DISEASES: FIRST CLINICAL STUDIES
Although preclinical data on the use of rhEPO and EPO variants have been promising for over a decade now, translation to humans has been extremely slow and difficult due to expiring patent protection for EPO worldwide, as well as reluctant public funding for trials that use drugs already approved for other indications. Therefore, despite worldwide interest of clinicians and clinical scientists, there are only a few trials published to date that have investigated efficacy of EPO in human brain disease. Very recently, two safety studies have been concluded in very preterm infants and infants with extremely low birth weight. 120, 121 In both studies, high-dose EPO was found well tolerated, causing no excess morbidity or mortality. A dose range of 1000 to 3000 IU/kg was found to yield neuroprotective serum levels. 121 Data on efficacy in these trials, however, are not yet available. Another study, including patients with subarachnoid hemorrhage, was recently published. 122 This study, unfortunately, had to be terminated prematurely due to poor recruitment efficiency. In this study, no conclusions on efficacy of EPO could be drawn. There are several studies just con-cluded, still ongoing or planned worldwide, applying EPO for treatment of human nervous system diseases. These include: trials on neurotrauma, subarachnoid hemorrhage, spinal cord injury, cerebral malaria, optic neuritis, Friedreich's ataxia, 123 chemotherapy induced peripheral neuropathy, and diabetes-associated complications of the nervous system (for overview, see Table 2 ). To our knowledge, no EPO variants other than rhEPO itself have thus far been published in relation to the treatment of human nervous system diseases. The only studies published so far reporting on efficacy of rhEPO in human brain diseases are our own studies on ischemic stroke, schizophrenia and MS. 69, 119, 124 
Stroke
As early as 1997, we started the first proof-of-concept trial. This endeavor was based on our own preclinical work and the conviction that, having a compound in hand that in other indications had proven safe and well tolerated in millions of people, it was more than justified to rapidly translate our findings with EPO to man. This approach was shortly afterward supported by the first publications on rodent studies from other groups, showing beneficial effects of EPO in hypoxia/ischemia.
2,4,67
The "Göttingen EPO Stroke Study" comprised a safety and double-blind, placebo-controlled part. 69 We included only patients suffering from acute ischemic stroke in the MCA territory to closely mimic the experimental setting of MCA occlusion. The idea was also to provide an optimal basis for comparison of both clinical and imaging readouts in the study population. EPO was infused intravenously over 3 days daily at a dose of 33,333 IU to result in a total dose of 100,000 IU per patient. The first study drug application was performed as rapidly as possible after the onset of stroke, allowing for a time window to treatment of not more than 8 h. The second and third dose was given at 24 h and 48 h later, respectively. EPO was found to be well tolerated and safe in stroke patients. The dose applied led to an increase of CSF EPO concentrations in stroke patients (with a disturbed bloodbrain barrier) of approximately 60 times the baseline level. 69 These findings encouraged continuation in form of a double-blind, placebo-controlled, randomized, proof-of-concept (phase IIb) study, which showed that EPO improved clinical outcome, indeed, and reduced evolution of lesion, as well as serum levels of the circulating glial damage marker, S100B, as compared to the placebo group. 69 Based on these very promising results, the German Multicenter EPO Stroke Trial (ClinicalTrials. gov Identifier: NCT00604630) was begun in February 2003, aiming at the inclusion of over 500 patients. The trial was performed in a multicenter setting within Germany, including university hospitals in Göttingen, Hannover, Bremen, Celle, Erlangen, Leipzig, Essen, Dresden, Braunschweig, Aachen, and Berlin. In the summer of 2008, the trial concluded. Of note is the fact that compared with the first EPO stroke study, the "stroke landscape" has changed due to approval of recombinant tissue plasminogen activator (rtPA) for treatment of ischemic stroke in Germany in the year 2000. As a result, a surprising amount of over 60% of the patients included in the German Multicenter EPO Stroke Trial received thrombolytic therapy. Therefore, for the currently running trial analysis, patients have to be divided into an rtPA and a non-rtPA population. At this point, the most important message may be that the results of the first trial have essentially been reproduced (manuscript in preparation).
Schizophrenia
In the meanwhile, basic research of our group and also of ever-increasing numbers of other groups continued. While the original idea was to use EPO to target acute brain diseases, exploiting its potent anti-apoptotic action, more and more data have recently been accumulated that have found a high regenerative potential of EPO, ranging from neurotrophic, neurogenesis, plasticity-modulating to angiogenetic properties. Therefore, we moved on to study the effect of long-term, high-dose EPO treatment in a chronic brain disease, schizophrenia. In preparation of this study, we first tested the capability of EPO to penetrate an intact blood-brain barrier. 27 Using indium-111-labelled EPO, we delivered proof-of-principle that even in healthy subjects, peripherally applied EPO can accumulate within brain tissue. The accumulation of labelled compound within the brain, however, was increased in schizophrenic patients as compared to healthy individuals. This is most likely due to the higher density of EPOR expression in the brains of schizophrenics. 27 In support of our planned trial on EPO in schizophrenia, we obtained an improvement of cognitive performance in rodents on EPO. 27 Very recently, we discovered that EPO is able to enhance hippocampal long-term and short-term potentiation and neuronal plasticity, considered prerequisites for learning and memory processes in this brain area. 125 Most intriguingly, we found that EPO prevents the development of slowly progressing global brain atrophy in a mouse model of chronic neurodegeneration. 86 The fact that EPO reduced in vitro haloperidolinduced death of primary hippocampal neurons, further encouraged continuation of our plans to use this compound for treating schizophrenic patients. 27 From 2003 to 2005, we performed a double-blind, placebo-controlled multicenter trial (phase IIb) on EPO add-on treatment in chronic schizophrenic men displaying a defined cognitive deficit. 124 Participating centers included Göttingen, Kiel, Homburg, Cologne and Marburg. High-dose EPO (40,000 IU intravenously), applied over 12 weeks on a weekly basis, led to significant improvement of schizophrenia-relevant cognitive performance as compared to placebo-treated patients. 124 In addition to the stepwise improvement in cognitive performance, we found that EPO was able to delay progression of cortical gray matter loss in chronic schizophrenic patients, as determined by most comprehensive, voxel-based morphometrical MRI analysis (manuscript in preparation). In this respect, EPO-induced prevention of brain atrophy, as observed in rodent studies, 86 could be nicely reproduced in man. In contrast, within the 3 months observation period, no EPO effect was noted on psychopathology (PANSS ratings) or psychosocial outcome parameters in the schizophrenic population. Taken together, the fact that EPO is the first compound ever that appears to exert a beneficial effect on cognition and reduction of cortical gray matter loss in schizophrenia should stimulate further work along these lines. A treatment trial including patients with a first episode of schizophrenic psychosis is presently being planned, as are further studies with chronic schizophrenic patients.
Multiple sclerosis
Encouraged by the neuroprotective/neuroregenerative effects of EPO seen in our human trials, and the increasing number of positive rodent studies on EAE and related conditions, 33, 67, [91] [92] [93] [94] [95] [96] we initiated another investigatordriven, exploratory, open-label study (phase IIa) addressing patients suffering from either primary or secondary chronic progressive MS. 119 The main objectives of this study were: 1) to evaluate safety of long-term, high-dose intravenous EPO treatment in MS; and 2) to collect first evidence of potential efficacy of EPO on the most MSrelevant clinical outcome parameters. The study design comprised a 6-week lead-in period set up to obtain a clean estimate of baseline performance, a 12-week treatment phase with weekly intravenous applications of EPO, followed by another 12-week treatment phase with bi-weekly EPO, and a 24-week post-treatment period. The individual study duration lasted for up to 1 year in total. Despite including only a small number of subjects, we were able to demonstrate that chronic progressive MS patients improved considerably with respect to motor function and cognition on high-dose, long-term EPO treatment. As compared to the efficacious 48,000 IU dose, "low-dose" treatment (8000 IU) did not yield any significant effects. Interestingly, two drug-naïve Parkinson patients, who also received high-dose EPO, did not improve over the 12-week weekly treatment period. Motor and cognitive improvement in high-dose MS patients were clearly visible already after the 12-week weekly treatment phase, remained stable over the following biweekly EPO period, and essentially persisted over the EPO-free follow-up time. Figure 3 illustrates the course of performance of high-dose EPO MS patients in selected tests, reflecting cognitive, as well as fine motor improvement. The hematocrit did not increase in parallel, but rather slightly decreased over the observation time in these patients. In the whole study, there were no safety concerns, no study drug-related adverse events reported or observed, and a surprisingly low need of blood lettings. We interpret the infrequent requirement of blood lettings in MS patients as a relative hyporesponsiveness of the hematopoietic system to EPO, as known in other diseases, characterized by a systemic latent inflammatory condition. 126 Therefore, EPO may well be the compound of choice for the indication MS where derivatives, harbouring neuroprotective, but no hematopoietic properties, may be unnecessary.
Precautions for the use of EPO in nervous system indications
The use of EPO as a neuroprotective/neuroregenerative treatment strategy in human brain disease, in particular when considering the high dose of EPO required to obtain sufficient levels within the brain in situations of widely intact blood-brain barrier, requires meticulous and comprehensive safety management. EPO in these indications will never be a "let go treatment." A close follow-up of patients at all times is mandatory, including clinical as well as laboratory examination combined with each and every EPO application.
Red blood cell parameters and iron
Hematocrit (hemoglobin) has to stay within clearly defined limits during EPO treatment. Even though the necessity of blood lettings in schizophrenics, and particularly in MS patients was very low, it is still of outmost importance to carefully follow each and every individual and to strictly initiate blood letting whenever the hematocrit increases over 48% in females and over 50% in males. Note that no iron substitution is allowed at any time. Iron would induce a push of red blood cell production, definitely undesirable in nervous system indications. Such a push may be helpful when EPO is used for treating anemia, but never in the treatment of brain diseases. In our studies, we actually exploit the fact that the need for blood lettings will undergo rapid self-limitation in the absence of iron substitution. Because EPO treatment leads to temporary shifts in iron stores, leading to laboratory readouts, similar to true iron deficiency, the patients themselves and all potentially involved physicians have to be made aware that iron substitution is not necessary and may be even damaging. With cessation of EPO treatment, most iron parameters will rapidly return to normal levels. 119, 124 Interestingly, the temporary reduction in iron availability caused by EPO might even provide an additional benefit in chronic progressive MS in which iron has even been seen as an inflammation-supporting agent, and iron chelators have been proposed for treating this condition.
127
Thrombocytes
Platelet counts have to be carefully and continuously monitored at all times of EPO treatment and even in the weeks thereafter. Patients with thrombocyte counts distinctly above the normal range have to be excluded at any time, be it on inclusion or during treatment with EPO. Although appreciable stimulation of thrombocytes occurs in only few patients, EPO is known to also act on megakaryocytes. 128 FIG . 4 illustrates the case of a male patient where, starting from normal levels, EPO treatment induced an increase in hematocrit/ hemoglobin   FIG. 4 . Course of hematocrit, hemoglobin, and thrombocytes in a 44-year-old, male patient, suffering from progressive supranuclear palsy, with high-dose weekly erythropoietin (EPO) treatment. At week 4, a first blood letting (arrow) had to be performed, due to an increase in hematocrit over the tolerable limit of 50%. Three days later, a second blood letting (arrow) corrected the still increased hematocrit back to baseline values. Hemoglobin levels behaved identically. In contrast, thrombocytes had also reached numbers distinctly above the normal limit at week 4, but did not respond to the two blood lettings with return to baseline level. Therefore, treatment with EPO was discontinued. The mean of two baseline measurements was set to 100% and was used for calculating individual course of laboratory values over time (expressed as percentage of baseline).
above the limit of 50% at week 4 of high-dose EPO treatment. Therefore, blood letting was performed in this patient twice (FIG. 4, see arrows) within 1 week, until complete normalization of hematocrit/hemoglobin was achieved. In this patient, thrombocyte counts had gradually increased to reach a level above normal at the time point of first blood letting. In contrast to hematocrit/ hemoglobin, however, blood letting did not lead to return of platelet counts to the individual baseline level. Therefore, this patient had to discontinue treatment with EPO to avoid any risk of thromboembolic complications. In addition, the patient received acetyl salicylic acid for 4 weeks (i.e., until platelets had returned to normal). Importantly, patients with past thromboembolic complications have to be strictly excluded. Exsiccosis has to be prevented at any time. Immobility poses a great risk for thromboembolic complications, and therefore patients who are prone to bed should not be included in a chronic treatment study. Furthermore, patients with cardiovascular disease or cardiovascular risk factors (e.g., diabetes, severe therapy-resistant hypertension, smoking, or contraceptive medication) have to be excluded.
Blood pressure
EPO is known to potentially induce increases in blood pressure in susceptible patients (e.g., patients with renal failure). 129, 130 Although no such increases have been clearly noted in any of the patients in our studies, blood pressure monitoring is absolutely essential and increases in blood pressure with EPO treatment have to be either pharmacologically controlled or should be considered as an exclusion criterion.
Tumors
Although the exact effects of EPO on tumor growth are still unclear and may not be the same in all kinds of tumors, patients suffering from any kind of malignancy, whether treated or untreated, should be strictly excluded from EPO treatment in the indications discussed here.
131-135
EPO antibody formation
Like all proteins, EPO has the potential to induce antibody formation. 74, 75 However, in contrast to e.g. insulin, this apparently occurs very rarely. In fact, a temporary problem of neutralizing antibody formation induced by EPO has recently been resolved. For several years, EPO antibody formation was observed more frequently with certain EPO preparations in which obvious components of packaging material (rubber stopper) acted as "Freud adjuvant." On changing of the packaging procedure and careful adherence to the cooling chain, no further reports on EPO antibody formation became publicly available. Nevertheless, antibody determination should be part of an EPO treatment program and should be performed before starting and after terminating EPO treatment in all patients with neurological or psychiatric indications. Importantly, EPO antibody formation has to be suspected at any time when reticulocyte counts drop below the normal range.
CONCLUSION
The promising results of clinical trials and exploratory clinical studies will hopefully encourage not only clinical scientists but also industry and public sponsors to perform further trials. Treatment of neuropsychiatric patients with EPO outside of studies can not be recommended at this time. In any case, meticulous adverse event monitoring and safety management, as well as most careful observation of potential contraindications, is absolutely mandatory. Even with future approval of EPO for nervous system indications, these safety rules should never be neglected; otherwise, a potentially highly beneficial drug will soon acquire a negative reputation.
